drugset

drugset / Trial / NCT00790426

Phase II Study of TKI258 in Advanced Urothelial Carcinoma

NCT00790426 ↗

Phase 2 Completed 44 enrolled Novartis Pharmaceuticals

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy of TKI258 in patients with advanced urothelial cancer

Timeline

Start: 2010-03
Primary completion: 2012-04
Completion: 2012-04

Publications

Milowsky MI, Dittrich C, Duran I, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn DI, Stadler WM, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec;50(18):3145-52. doi: 10.1016/j.ejca.2014.10.013. Epub 2014 Oct 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dovitinib	Small molecule	500 mg	—

Indications